MedTrace Logo

Repetitive Transcranial Magnetic Stimulation in Pharmaco-naïve Patients With Major Depression

NCT04000022 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-05-25

No results posted yet for this study

Summary

Repetitive transcranial magnetic stimulation (rTMS) has become a safe and efficacious treatment for patients with treatment-resistant depression. In several studies investigating the antidepressant efficacy of rTMS, it has been shown that in low treatment-resistant patients rTMS is more efficacious than in patients where several treatment attempts have failed. Albeit this finding, most studies to date primarily recruited patients with relatively high degrees of treatment-resistance and there is a lack of trials investigating rTMS as a first-line treatment. Therefore, this trials aims to compare the antidepressant efficacy of 4 weeks open-label theta-burst TMS in non-treatment-resistant patients with a comparable group of treatment-resistant MDD patients.

Conditions

Interventions

DEVICE

intermittent theta burst stimulation (iTBS)

20 sessions of iTBS

Sponsors & Collaborators

  • Maximilian Kiebs, M.S.

    collaborator UNKNOWN

  • Clemens Mielacher, M.S.

    collaborator UNKNOWN

  • University Hospital, Bonn

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2023-12-29
Completion
2024-05-01
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04000022 on ClinicalTrials.gov